Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - ONYX PHARMACEUTICALS INC | f58570e10vq.htm |
| EX-31.1 - EX-31.1 - ONYX PHARMACEUTICALS INC | f58570exv31w1.htm |
| EX-31.2 - EX-31.2 - ONYX PHARMACEUTICALS INC | f58570exv31w2.htm |
| EX-10.1.I - EX-10.1(I) - ONYX PHARMACEUTICALS INC | f58570exv10w1wi.htm |
| EX-10.13.V - EX-10.13(V) - ONYX PHARMACEUTICALS INC | f58570exv10w13wv.htm |
| EX-10.22.II - EX-10.22(II) - ONYX PHARMACEUTICALS INC | f58570exv10w22wii.htm |
| EXCEL - IDEA: XBRL DOCUMENT - ONYX PHARMACEUTICALS INC | Financial_Report.xls |
EXHIBIT 32.1
CERTIFICATION
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United
States Code (18 U.S.C. § 1350), N. Anthony Coles, President and Chief Executive Officer of Onyx
Pharmaceuticals, Inc. (the “Company”), and Matthew K. Fust, Executive Vice President and Chief
Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:
| 1. | The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2011, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and | |
| 2. | The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Periodic Report and results of operations of the Company for the period covered by the Periodic Report. |
Dated: May 10, 2011
| /s/ N. Anthony Coles | ||||
| N. Anthony Coles | ||||
| President and Chief Executive Officer (Principal Executive Officer) |
||||
| /s/ Matthew K. Fust | ||||
| Matthew K. Fust | ||||
| Executive Vice President and Chief
Financial Officer (Principal Financial and Accounting Officer) |
||||
A signed original of this written statement required by Rule 13(a)-14(b) of the Exchange Act and
Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350) has been
provided to Onyx Pharmaceuticals, Inc. and will be retained by Onyx Pharmaceuticals, Inc. and
furnished to the Securities and Exchange Commission or its staff upon request.
“This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the
Securities and Exchange Commission and is not to be incorporated by reference into any filing of
Onyx Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of
any general incorporation language contained in such filing.”